Prevalence and time trends of neural tube defects in regions of the Russian Federation

Neural tube defects – a group of severe congenital malformations with a high level of mortality, childhood disability. The average prevalence of these defects is approximately 1 per 1000 births. The main measures to reduce the prevalence of neural tube defects are primary and secondary prevention measures, the effectiveness of which can be determined by congenital malformations monitoring.

Research purpose. To determine the prevalence of neural tube defects, as well as trends in their prevalence for 2011 to 2017 in the Russian Federation according to monitoring of congenital malformations.

Results. The total prevalence of anencephaly among newborns and fetuses was 4.63 (95% confidence interval - CI 4.40–4.88) per 10000 births, spina bifida – 6.18 (95% CI 5.91–6.46) and encephalocele 1.34 (95% CI 1.21–1.47). At the same time, the prevalence of anencephaly only among live births was 0.11 (95% CI 0.08–0.15) per 10000, spina bifida – 2.24 (95% CI 2.08–2.41) and encephalocele – 0 25 (95% CI 0.20–0.31). The decrease in prevalence of birth defects among live births compared with the total prevalence is provided by a high level of detection of these defects by ultrasound examination during pregnancy with the subsequent elimination of the affected fetuses. The maximum proportion of eliminated fetuses is observed for anencephaly (90.5%), for encephalocele the proportion of aborted fetuses is 77.4% and for spina bifida – 59.3%. Over the 7-year period, the multidirectional prevalence trends were noted: the increasing trend for total prevalence of neural tube defects and the decreasing trend for prevalence of these defects among live-born children.

Conclusion. Estimates of the prevalence of neural tube defects in Russian Federation regions are obtained. The dynamics of the studied defects prevalence indicates that the decreasing of neural tube defects prevalence among live births is associated with secondary prevention measures.

1. Rofail D., Maguire L., Kissner M., Colligs A., Abetz-Webb L. A review of the social, psychological, and economic burdens experienced by people with spina bifida and their caregivers. Neurol Ther 2013; 2: 1–12. DOI: 10.1016/j.ejogrb.2014.07.048

2. Loane M., Dolk H., EUROCAT Working Group. Special report: Prevalence of Neural Tube Defects in younger mothers in Europe 2000–2008: Analysis of the EUROCAT database. 2010; 1–16. http://www.eurocat-network.eu/prevdata

3. Khoshnood B., Loane M., de Walle H., Arriola L., Addor M-C., Barisic I. et al. Long term trends in prevalence of neural tube defects in Europe: population based study. BMJ 2015; 351: h5949. DOI: 10.1136/bmj.h5949

4. Czeizel A.E., Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–1835.

5. Sixty-third World Health Assembly. Birth defects. Report by the Secretariat. 2010; 1–7.

6. Kozlova S.I., Prytkov A.N., Demikova N.S. Birth defects monitoring. Moscow: RMAPO, 2000; 34 (in Russ.)

7. Demikova N.S., Kobrinsky B.A. Principles for the organization of birth defects monitoring and its implementation in the Russian Federation. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2001; 46(4): 56–60 (in Russ.)

8. Omer L.M., Abdullah O.M., Mohammed I.N., Abbasher L.A. Research: Prevalence of neural tube defects Khartoum, Sudan August 2015–July 2015. BMC Research Notes 2016; 9: 495–498. DOI : 10.1186/s13104-016-2298-6

9. Stoll C. Distribution of single organ malformations in European populations. Ann Genet 1995; 38(1): 32–43.

10. Smithells R.W., Nevin N.C., Seller M.J., Sheppard S., Harris R., Read A.P. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1: 1027–1031.

11. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338: 131–137.

12. Oakley G. The Scientific Basis for Eliminating Folic Acid–Preventable Spina Bifida: A Modern Miracle from Epidemiology. Ann Epidemiol 2009; 19: 226–230. DOI : 10.1016/j.annepidem.2009.01.016

13. https://eu-rd-platform.jrc.ec.europa.eu/eurocat/prevention-and-risk-factors/folic-acid-neural-tube-defects. Ссылка актуальна на 23.09.2019 г.

14. Blencowe H., Kancherla V., Moorthie S., Darlison M.V., Modell B. Estimates of global and regional prevalence of neural tube defects for 2015: a systematic analysis. Ann N Y Acad Sci 2018; 1414(1): 31–46. DOI: 10.1111/nyas.13548

15. Kancherla V., Wagh K., Johnson Q., Oakley G.P. A 2017 global update on folic acid preventable spina bifida and anencephaly. Birth Defects Res 2018; 110(14):1139–1147. DOI: 10.1002/bdr2.1366

16. Busby A., Abramsky L., Dolk H., Armstrong B. Preventing neural tube defects in Europe: population based study. BMJ 2005; 330: 574–575.

17. Khoshnood B., Greenlees R, Loane M, Dolk H. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res A Clin Mol Teratol 2011; 91(suppl 1): S16–22. DOI: 10.1002/bdra.20776

18. EUROCAT Folic Acid Working Group. EUROCAT special report: prevention of neural tube defects by folic acid supplementation in Europe. 2009. https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/eurocat-pub-docs/Special-Report-NTD-3rdEd-2009.pdf. Ссылка актуальна на 23.09.2019 г.